Jane Osbourn is Alchemab’s Chief Executive Officer and provides overall leadership to the company. Prior to joining Alchemab, Jane served as Vice President of R&D at MedImmune, the biologics arm of AstraZeneca, where she contributed to the development of antibody phage display technology, authored key publications and patents and contributed to the discovery and development of a number of marketed antibody therapies including HUMIRA® (adalimumab) and IMFINZI® (durvalumab).

Jane chairs the Cambridge-based cell therapy company Mogrify, has served as a Director of Babraham Bioscience Technologies, and Cambridge Enterprise, and is a member of the Crick Translational Advisory Group. Previously, she served as a Member of the UK Medical Research Council Industry Grant Award Assessment Panel, and from 2015-2019, served as Chair of the Board of Directors of the UK BioIndustry Association.

Jane was awarded an Order of the British Empire (OBE) and Scrip’s Lifetime Achievement Award in 2019 for services to drug discovery, development and biotechnology. She earned a PhD from the John Innes Centre for Plant Science Research in Norwich and BA in Natural Sciences (First Class: Biochemistry) from the University of Cambridge.